Navigation Links
TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
Date:11/25/2008

LA JOLLA, Calif., Nov. 25 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has purchased from Eli Lilly & Company a reduction in certain royalty amounts that may become payable to Eli Lilly on net sales of TorreyPines' clinical-stage compounds NGX426 and tezampanel, should either or both gain regulatory approval. Specifically, the top tier royalty rate will be reduced three percentage points and the middle tier royalty rate will be reduced one half percentage point. The bottom tier royalty rate will remain unchanged. In addition, certain milestone payments due to Eli Lilly related to the clinical development of NGX426 will be delayed from what was originally agreed. In exchange for the royalty rate reduction and change in milestone payment timing, TorreyPines issued to Eli Lilly two hundred thousand shares of TorreyPines Common Stock at fair market value. TorreyPines originally licensed NGX426 and tezampanel from Eli Lilly in April 2003.

"This agreement with Eli Lilly is another important part of our 2008 strategic plan to strengthen the company and build stockholder value," said Ev Graham, Chief Executive Officer of TorreyPines. "We believe the royalty rate reduction and delay in certain clinical milestone payments for NGX426 will further enhance the commercial value of NGX426 and tezampanel."

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognit
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
2. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
3. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
4. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
5. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
6. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
7. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
8. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
9. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
10. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
11. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009).... , Whether it,s CD packaging, containers or...Identification) are increasingly finding their way...l objects or goods and identify them automatically...ead and process the data contained in the label. S...on conditions of up to 100 degrees Celsius. But at...
(Date:11/24/2009)...nvestment bank KTA Capital,s client Neuren Pharmac...nvertible note private placement with a U.S. insti...ged by KTA Capital as Neuren,s exclusive placement... York (PRWEB) November 23, 2009 -- The independent...KTA Capital") has announced that its client N...
(Date:11/24/2009)...ewswire-FirstCall/--deCODE,genetics,Inc.(Nasdaq: D...NasdaqStockMarketthattradinginthecompany,scommonst...SEwillbefiledwiththe,SecuritiesandExchangeCommissi...nNasdaq,unlessthecompanyfilesanappealtotheNasdaq,L...appeal,which,willstaythesuspensionanddelistingthro...
(Date:11/24/2009)...ewswire-FirstCall/--deCODE,genetics,Inc.(Nasdaq: D..."motionsbytheU.S.BankruptcyCourtfortheDistrictofDe...voluntarypetitionfor,reliefunderChapter11oftheUnit..., TheordersissuedbytheBankruptcyCourtallowthecom...r11proceedings.Inparticular,the,companyreceivedint...
Breaking Biology Technology:Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
...armaceuticals, the proprietary products division o...Companies, Inc. (NYSE: PRX ) today,announced that... Inc.,(Amex: IMM ) has chosen to discontinue the ...nvestigative therapy., On February 22, 2008, Immt...rts of adverse events related to abnormal kidney f...
...agene Inc., a,biotechnology company that develops ... announced today that one of the Nature Research,J...he FACTORIAL(TM). In,advance online publication on...colleagues describes a novel and remarkably consis...tivity of a large panel of transcription,factors.,...
...l/ - Oncothyreon Inc. (Nasdaq,- ONTY) (TSX - ONY) ...f,data demonstrating the effectiveness of PX-478 i...8th Annual Targeted Therapies of the Treatment of,...on for the Study of Lung,Cancer in Santa Monica, C...2008, by Jorg J. Jacoby, Ph.D., Instructor, Univer...
Other Biology Technology:Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine 2Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine 3Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 2Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 3Oncothyreon's PX-478 is effective in preclinical model of human lung cancer 2Oncothyreon's PX-478 is effective in preclinical model of human lung cancer 3
(Date:11/23/2009)... , CINCINNATINew research presents strong evidenc...sure to both outdoor traffic-related pollution and...ungs than one or the other exposure alone. , E...f Cincinnati (UC) College of Medicine have shown t...c-related particles and indoor endotoxin during ea...
(Date:11/23/2009)... , TORONTO, November 23, 2009 - The time of day...ording to a new paper produced by a research team ...oronto Scarborough,s vice-principal for research a...s biology at the St. George campus. , Capitali...f the poplar tree, the research team examined how ...
(Date:11/23/2009)... , Farmington, CT Current research suggests that... disease. The related report by Nichols et al, "U...nt a New Class of TLR2 Ligands Capable of Enhancin...e of The American Journal of Pathology . , Mult...stem attacks the brain and spinal cord, affects ne...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Factors from common human bacteria may trigger multiple sclerosis 2Diabetes drug kills cancer stem cells in combination treatment in mice 9909 1Diabetes drug kills cancer stem cells in combination treatment in mice 9909 2Diabetes drug kills cancer stem cells in combination treatment in mice 9909 3Alert status area in brain discoved by Hebrew University scientists 9907 1Alert status area in brain discoved by Hebrew University scientists 9907 2Translational Research 3A From Bench to Bedside Capitol Hill Breakfast Briefing Hosted by the Council for American Medical Innovation 57026 1Translational Research 3A From Bench to Bedside Capitol Hill Breakfast Briefing Hosted by the Council for American Medical Innovation 57026 2
...oth pass on "traditions" to other members of their...ng behaviour. The findings add to evidence that cu...e study involved killerwhales at Marineland in Nia...evised a brand new way to catch birds, and passed ...orca lures gulls into his tank by spitting regurgi...
...ribed to patients with the common cold because the...nd the benefits do not outweigh the risks, accordi... , "Antibiotics appear to have no benefit in the t...ns," conclude Dr. Bruce Arroll and Dr. Timothy Ken...The implications for practice are that prescriptio...
...ands of biologists around the globe run DNA sequen...nline algorithm called BLAST ?typically submitting...de, to be matched against the billions of letters ...an shed light on functional or evolutionary relati...hrough and produce vast amounts of data. Everyday ...
Other Biology News:More animals join the learning circle 2Doctors should stop prescribing antibiotics for the common cold, review advises 2Drawing with DNA: 'Bioart' illuminates genomics 2Drawing with DNA: 'Bioart' illuminates genomics 3
DHFR-1 FP-1 Forward Sequencing Primer from EPICENTRE Biotechnologies
Human Mesenchymal Stem Cell Functional Identification Kit from R&D Systems
Rabbit Anti-Syntrophin alpha 1 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Human HLA Class 1 A25 Monoclonal Antibody, Unconjugated, Clone 4i97 from Abcam
Biology Products: